| Literature DB >> 28906488 |
Ping Han1,2, Ren-Hui Chen1,2, Fang Wang3, Jia-Yi Zeng4, Shi-Tong Yu1,2, Li-Hua Xu5, Qian Cai1,2, Fa-Ya Liang1,2, Tian-Liang Xia4, Zhi-Rui Lin4,6, Qian Zhong7, Xiao-Ming Huang1,2.
Abstract
Recently, chimeric transcripts have been found to be associated with the pathogenesis and poor prognosis of malignant tumors. Through our preliminary experiment, a novel chimeric transcript called chimeric transcript RRM2-c2orf48 was detected in C666-1, a classical cell line of human nasopharyngeal carcinoma (NPC). Therefore, the objective of this study was to demonstrate the existence and expression of novel chimeric transcript RRM2-c2orf48 and to explore the main functions and mechanisms of RRM2-c2orf48 in NPC. In this study, the expression of RRM2-c2orf48 was evaluated in NPC cells and specimens. Effects of RRM2-c2orf48 on migration and invasive capacities were detected in vivo and vitro. Moreover, ways in which RRM2-c2orf48 increases the invasive capacities of NPC were explored. As a result, the presence of novel chimeric transcript RRM2-c2orf48 was confirmed in C666-1 by RT-PCR and sequencing, and it was a read-through between RRM2 and c2orf48 through the transcription of interchromosome. Higher expressions of novel RRM2-c2orf48 were detected in NPC cell lines and NPC tissue specimens relative to the controls and its expression was be statistically relevant to TNM staging. High level of RRM2-c2orf48 could increase the migration and invasive capacities of NPC cells, potentially as a result of NPC cell epithelial-mesenchymal transition. RRM2-c2orf48 could also enhance resistance of chemotherapy. In vivo, RRM2-c2orf48 could enhance lung and lymph node metastasis in nude mice. These results demonstrate that high levels of RRM2-c2orf48 expression may be a useful predictor of NPC patients of metastatic potency, presenting potential implications for NPC diagnosis and therapy.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28906488 PMCID: PMC5636969 DOI: 10.1038/cddis.2017.402
Source DB: PubMed Journal: Cell Death Dis Impact factor: 8.469
Figure 1Paired-end RNA-seq data and fusion gene analysis. (a) RNA-seq experiment process. (b) Data statistics and reads comparison between NPEC2 and C666-1; the unique reads ratio of both templates was >80%. (c) The gene coverage results show that the ratio of gene coverage reaching >70% was 55% and 69% in NPEC2 and C666-1, respectively. (d) The representative 1% agarose gel image of the amplification of chimeric transcript RRM2-c2orf48 by templates of cDNA from nasopharyngeal carcinoma cell line C666-1 and nasopharyngeal epithelium NPEC2 cells. The specific PCR product of RRM2-c2orf48 is approximately 600 bp in C666-1 but not in NPEC2. (e) Sequencing results show the chimeric site between RRM2 and c2orf48 at the mRNA level. (f) Formation model of chimeric transcript RRM2-c2orf48: RRM2 is located on chromosome 2p25-24, and c2orf48 is located on 2p25.1. During transcription, read-through occurred between RRM2 exon9 and c2orf48 exon 1. As a result, a new protein with 374 amino acids that was shorter than the wild-type RRM2 was produced (389 amino acids)
Figure 2RRM2-c2orf48 expression in NPC. (a) The expression level of RRM2-c2orf48 mRNA in nasopharyngeal carcinoma cell lines (CNE1 to HNE1) was higher than that in normal nasopharyngeal epithelium cells (N01–09) and in immortalized nasopharyngeal cell lines (NPEC1-2 Bmi-1) by real-time PCR. (b) The expression level of RRM2-c2orf48 mRNA in nasopharyngeal carcinoma specimens was higher than that in the control specimens by real-time PCR (P=0.03). (c) Amplification of RRM2-c2orf48 and wild-type RRM2, c2orf48 in C666-1 cDNA. Electrophoresis results of 1% agarose gel show a specific band with lengths of RRM2 (1170 bp, nm_001034), RRM2-c2orf48 (1125 bp) and c2orf48 (480 bp, nm_182626), respectively. (d) RRM2-c2orf48 (43 kd), RRM2 (45 kd) and c2orf48 (17 kd) expression was detected in HNE1 PMSCV or HNE1 PMSCV-flag-c2orf48/RRM2/c2orf48 cell lines using anti-flag antibodies by western blotting. (e) ELISA result of a new synthesized polyclonal antibody against the chimeric region of RRM2-c2orf48. (f) The band of RRM2-c2orf48 can be identified from anti-flag and synthesized antibody. (g) To confirm the specificity of synthesized antibody, immunofluorescence was used in NPC cell lines HNE1 and C666-1, expressing lower and higher RRM2-c2orf48, respectively. And RRM2-c2orf48 was located in cytoplasm. (h) RRM2-c2orf48 protein expression in most of the NPC cell lines was higher than that in NPEC1 Bmi-1
Figure 3Representative IHC staining of RRM2-c2orf48 in NPC specimens. (a) Nearly negative expression of RRM2-c2orf48; intensity level scored as 0. (b) Weak expression of RRM2-c2orf48; intensity level scored as 1. (c) Moderate expression of RRM2-c2orf48; intensity level scored as 2. (d) Strong expression of RRM2-c2orf48; intensity level scored as 3
Correlation between RRM2-c2orf48 expression and clinicopathologic characteristics in NPC patients
| 0.354 | ||||
| <46 | 80 | 36 (37.9%) | 44 (44.4%) | |
| ≥46 | 114 | 59 (62.1%) | 55 (55.6%) | |
| 0.887 | ||||
| Male | 140 | 69 (72.6%) | 71 (71.7%) | |
| Female | 54 | 26 (27.4%) | 28 (28.3%) | |
| 0.001 | ||||
| T1–2 | 88 | 55 (57.0%) | 33 (33.3%) | |
| T3–4 | 106 | 40 (42.1%) | 66 (66.7%) | |
| 0.025 | ||||
| N0–1 | 130 | 71 (74.7%) | 59 (59.6%) | |
| N2–3 | 64 | 24 (25.3%) | 40 (40.4%) | |
| 0.062 | ||||
| M0 | 148 | 78 (82.1%) | 70 (70.7%) | |
| M1 | 46 | 17 (17.9%) | 29 (29.3%) | |
| <0.001 | ||||
| I–II | 63 | 43 (45.3%) | 20 (20.2%) | |
| III–IV | 131 | 52 (54.7%) | 79 (79.8%) | |
| 0.740 | ||||
| NKUC | 145 | 70 (73.7%) | 75 (75.8%) | |
| NKDC | 49 | 25 (26.3%) | 24 (24.2%) | |
| 0.009 | ||||
| Survive | 123 | 69 (72.6%) | 54 (54.5%) | |
| Death | 71 | 26 (27.4%) | 45 (45.5%) | |
Abbreviations: NKDC, non-keratinizing differentiated carcinoma; NKUC, non-kertinizing undifferentiated carcinoma.
P<0.05.
Figure 4Survival analysis of RRM2-c2orf48 expression in NPC. (Number of patients at different time point was shown below the curve). (a) The five-year OS rate of the cohort of 194 NPC patients was measured as 63.4%. (b) The Kaplan–Meier and log-rank test analyses show that the cumulative 5-year survival rate reached 54.5% in the high RRM2-c2orf48 expression group, whereas it reached 72.6% in the low RRM2-c2orf48 expression group (P<0.01). (c) The association between high RRM2-c2orf48 expression and shorter OS was significantly stronger in patients occupying M1 stages than in those occupying M0 stages (P<0.05). (d) The association between high RRM2-c2orf48 expression and shorter OS was significantly stronger in patients occupying N0–1 stages than in those occupying N2–3 stages (P>0.05). (e) Disease-free survival (DFS) in patients presenting high RRM2-c2orf48 protein expression (130.3 months) were lower than those in patients presenting low RRM2-c2orf48 expression (141.2 months). P=0.022
Univariate and multivariate Cox regression analysis of different prognostic variables in NPC patients
| RRM2-c2orf48 expression | High | 1.888 (1.164–3.063) | 0.010 |
| Age (years) | >46 | 0.767 (0.481–1.224) | 0.266 |
| Gender | Female | 1.045 (0.623–1.753) | 0. 868 |
| T staging | T1–2 | 0.539 (0.330–0.882) | 0.014 |
| N staging | N0–1 | 0.508 (0.319–0.811) | 0.005 |
| Metastasis | Yes | 2.711 (1.677–4.381) | <0.001 |
| UICC 2008 stage | I–II | 0.350 (0.188–0.651) | 0.001 |
| WHO histological classification | NKDC | 0.563 (0.303–1.048) | 0.070 |
| Metastasis | Yes | 2.043 (1.221-3.418) | 0.007 |
| UICC 2008 stage | I–II | 0.460 (0.236-0.896) | 0.022 |
P<0.05.
Figure 5RRM2-c2orf48 enhances cancer cell migration and NPC invasion. (a) Establishment of stable cell lines of overexpressed RRM2-c2orf48 and confirmed by western blotting. In vitro, cell lines deformed to longer and thinner after overexpressed RRM2-c2orf48. (b) NPC cell lines of overexpressed RRM2-c2orf48 healed the wound ~72 or 48 h after serum starvation. (c) RRM2-c2orf48 overexpression increased the number of HNE1 cells invaded through the matrigel-covered chamber transwell. (d) The ratio of metastatic inguinal lymph nodes to the total number of inguinal lymph nodes dissected was markedly higher in the CNE2-RRM2-c2orf48 group (92.3%, 12/13) than in the vector-control group (53.8%, 7/13). (e) The ratio of HPRT in humans to β-actin in mice was used to confirm the existence of human cells in inguinal lymph nodes. (f) The ratio of lung metastases to the total number of mice was markedly higher for the CNE2-RRM2-c2orf48 group (40%, 4/10) than for the vector-control group (0%, 0/10). (g) H&E staining results confirm the existence of lung metastasis
Figure 6RRM2-c2orf48 induces NPC cell epithelial–mesenchymal transitioning and regulates signal pathways. (a) Microarray analysis of EMT-related markers. (b) Protein levels of EMT markers and transcript factors changed in RRM2-c2orf48 overexpressed cell lines